Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 23, 2026, Avantor, Inc.…
Filed Aug 27, 2026Accepted Aug 27, 2026, 4:40 PM EDTCIK 1722482Accession 0001628280-26-059273
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit corporate.avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 23, 2026, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) disclosing that Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, would transition to a new role supporting the Company’s segment integration activities for a period of time, after which he would depart the Company. The Original 8-K did not include Mr. Gourdier’s departure date because, at the time, his departure date had not been determined. This Form 8-K/A is being filed for the purpose of providing Mr. Gourdier’s departure date.
On August 21, 2026, the Company, through its subsidiary VWR International, LLC, and Mr. Gourdier agreed to a transition arrangement (the “Transition Agreement”), pursuant to which Mr. Gourdier will continue his employment with the Company through October 14, 2026, after which his employment will end. If Mr. Gourdier remains employed and complies with the terms of the Transition Agreement until October 14, 2026, he will be entitled to receive severance benefits materially consistent with the terms of the Company’s Executive Severance and Change in Control Plan, which are described in the Company’s proxy statement filed with the Securities and Exchange Commission on March 27, 2026.